[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"flap-necrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:flap-necrosis":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,63,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":39,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100592462","effect-of-dexmedetomidine-on-microsurgery-reconstruction-in-cancer-patient-100592462",false,"NCT06993740","Effect of Dexmedetomidine on Microsurgery Reconstruction in Cancer Patient","The Effect of Dexmedetomidine Administration on the Success of Reconstructive Microsurgery in Cancer Patients: A Study of Glycocalyx Integrity, Inflammatory Response, Thrombosis, Angiogenesis, Oxidative Stress, and Tissue Microcirculation","DEXFLAP","Inclusion Criteria:\n\n1. Adult patients (aged 18-65 years) diagnosed with cancer who are scheduled to undergo microsurgical flap reconstruction.\n2. Patients within the age range of 18 to 65 years at the time of enrollment.\n3. Patients who provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Patients with a history of uncontrolled diabetes mellitus.\n2. Patients diagnosed with chronic kidney disease.\n3. Patients with known liver failure.\n4. Patients receiving corticosteroid therapy prior to surgery.\n5. Patients with uncontrolled hypertension.\n6. Patients with a history of chemotherapy or radiotherapy prior to surgery.\n7. Patients diagnosed with preoperative sepsis.\n8. Patients requiring perioperative vasopressor support.\n9. Patients with a history of prior surgery in the same operative field.\n10. Patients who decline to participate in the study.","ALL","18 Years","65 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This double-blinded randomized controlled trial aims to investigate the effect of intraoperative dexmedetomidine administration on early flap viability and microvascular integrity in cancer patients undergoing elective microvascular reconstructive surgery. The primary outcome is clinical flap viability within 48 hours postoperatively, assessed using a standardized scoring system based on flap color, temperature, capillary refill time, and tissue turgor. Secondary outcomes include the evaluation of biomarkers related to endothelial glycocalyx degradation (syndecan-1), oxidative stress (SOD-1), inflammation (IL-6, IL-10), thrombosis (PAI-1), and angiogenesis (VEGF), as well as microcirculatory assessment using Sidestream Dark Field (SDF) imaging. The study is designed to determine whether dexmedetomidine improves early surgical outcomes by modulating pathophysiological processes involved in microvascular flap success.",[28,29,30,31,32,33,34,35,36,37,38],"Flap Monitoring","Inflammation","Thrombosis","Oxidative Stress","Glycocalyx","Anesthesia","Surgery","Flap Ischemia","Flap Necrosis","Flap Failure Risk Factors","Microsurgery",[40,41,42,43,44,45,46,47,48,49],"SOD-1","IL-6","IL-10","VEGF","Syndecan-1","Dexmedetomidine","SDF","PAI-1","Flap Failure","Flap Salvage","RECRUITING","2025-06-11",{"date":53,"type":54},"2025-06-15","ACTUAL",{"date":56,"type":54},"2025-06-10",{"date":58,"type":22},"2026-08-22",{"name":60,"class":61},"Dharmais National Cancer Center Hospital","OTHER_GOV",2,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":70,"minAge":18,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":23,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":88},"100578481","this-study-aims-to-explore-the-efficacy-of-hyperbaric-oxygen-in-the-treatment-of-flap-ischaemic-necrosis-after-breast-cancer-surgery-100578481","NCT06811857","This Study Aims to Explore the Efficacy of Hyperbaric Oxygen in the Treatment of Flap Ischaemic Necrosis After Breast Cancer Surgery","An Exploration of Hyperbaric Oxygen in the Treatment of Flap Ischaemic Necrosis After Breast Cancer Surgery","Inclusion Criteria:\n\n1. understand the study procedure, participate in the study voluntarily and sign the informed consent form\n2. aged ≥ 18 years and ≤ 60 years, female\n3. ECOG 0-2\n4. patients with The SKIN Score Degree of B-D and The SKIN area of 1-3 in the Clavien-Dindo classification after breast cancer surgery；\n\nExclusion Criteria:\n\n1. Contraindications to hyperbaric oxygen therapy: lung disease (severe chronic obstructive airway disease, herpetic lung disease, acute or chronic lung infection, uncontrolled asthma, untreated pneumothorax), history of previous middle ear surgery, middle ear disease (Eustachian tube dysfunction, recurrent episodes of vertigo), eye disease (retinal detachment).\n2. Pregnancy or lactation.\n3. any other condition that the investigators think the patient is unsuitable for participation in the study","FEMALE","60 Years",{"count":73,"type":22},76,[25],"The expectation of our study was to explore the efficacy of using hyperbaric oxygen to rescue flap ischaemic necrosis after breast cancer surgery.",[36,35],"NOT_YET_RECRUITING","2025-02-01",{"date":80,"type":54},"2025-02-06",{"date":82,"type":22},"2025-01-31",{"date":84,"type":22},"2027-01-31",{"name":86,"class":87},"Guangdong Provincial People's Hospital","OTHER",1,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":23,"phases":98,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":88},"100357522","monitoring-of-the-bone-free-flaps-with-microdialysis-100357522","NCT03935139","Monitoring of the Bone Free Flaps With Microdialysis","MTM2018","Inclusion Criteria:\n\n* adult person\n* signed informed consent\n* head and neck reconstruction with iliac crest or fibula free flap\n* patient covered by national health insurance\n\nExclusion Criteria:\n\n* minor person\n* head and neck reconstruction with other types of free flaps than crest or fibula free flap\n* pregnant or breastfeeding women",{"count":97,"type":22},40,[25],"Microdialysis is admitted to be reliable by numerous surgeons to monitor flaps. Nevertheless, a few authors reported follow up with microdialysis in bone free flaps, and they all describe the position of the catheter in the surrounding soft tissue muscle which is not the accurate reflect of bone vascularisation. The aim of this study is to determine the lactate\u002Fpyruvate ratio mean value in bone free flaps with a microdialysis catheter directly positioned in the bone tissue.",[36],[102,103,104,105],"microdialysis","bone free flap","fibula","iliac crest","2024-07-09",{"date":108,"type":54},"2024-07-10",{"date":110,"type":54},"2019-07-22",{"date":112,"type":22},"2025-07",{"name":114,"class":87},"Centre Hospitalier Universitaire, Amiens"]